Raymond James & Associates Buys 1,155 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Raymond James & Associates raised its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) by 2.7% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 43,397 shares of the life sciences company’s stock after purchasing an additional 1,155 shares during the quarter. Raymond James & Associates’ holdings in Integra LifeSciences were worth $1,838,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of IART. First Horizon Advisors Inc. acquired a new position in Integra LifeSciences during the second quarter valued at approximately $54,000. Aubrey Capital Management Ltd acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at $76,000. Covestor Ltd increased its position in shares of Integra LifeSciences by 63.0% in the 1st quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock valued at $100,000 after buying an additional 602 shares in the last quarter. Captrust Financial Advisors raised its stake in Integra LifeSciences by 95.0% during the 1st quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock worth $129,000 after buying an additional 976 shares during the period. Finally, PDT Partners LLC bought a new position in Integra LifeSciences during the second quarter worth about $206,000. 87.60% of the stock is owned by institutional investors.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $56.93 on Tuesday. The firm has a market capitalization of $4.75 billion, a P/E ratio of 27.64, a price-to-earnings-growth ratio of 1.59 and a beta of 1.14. The company has a current ratio of 3.93, a quick ratio of 2.91 and a debt-to-equity ratio of 0.86. The firm’s fifty day moving average price is $55.77 and its two-hundred day moving average price is $51.66. Integra LifeSciences Holdings Co. has a 1 year low of $40.67 and a 1 year high of $68.29.

Integra LifeSciences (NASDAQ:IARTGet Rating) last issued its earnings results on Wednesday, October 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14. Integra LifeSciences had a net margin of 11.05% and a return on equity of 16.41%. The company had revenue of $385.19 million for the quarter, compared to analysts’ expectations of $377.79 million. As a group, research analysts anticipate that Integra LifeSciences Holdings Co. will post 3.33 EPS for the current year.

Analyst Ratings Changes

IART has been the subject of several research analyst reports. Jefferies Financial Group started coverage on Integra LifeSciences in a research report on Tuesday, October 11th. They issued a “hold” rating and a $48.00 price objective for the company. TheStreet raised shares of Integra LifeSciences from a “c+” rating to a “b-” rating in a research report on Tuesday, December 27th. Morgan Stanley increased their target price on Integra LifeSciences from $50.00 to $59.00 and gave the stock an “equal weight” rating in a report on Friday, January 6th. Citigroup boosted their price target on Integra LifeSciences from $50.00 to $60.00 and gave the company a “neutral” rating in a report on Monday, December 12th. Finally, Truist Financial increased their price objective on Integra LifeSciences from $52.00 to $58.00 and gave the stock a “hold” rating in a report on Tuesday, December 20th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $58.33.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.

Read More

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.